Novartis India to Acquire Minipress, Minipres Trademarks From Pfizer for Rs 1,250 Crore
Mumbai: Novartis India Limited has approved the acquisition of the Minipress and Minipres trademarks registered in India, along with certain related intellectual property rights, from Pfizer Inc., USA, and Pfizer Products Inc., USA, for an aggregate consideration of Rs 1,250,00,10,000 (Rs 1,250 crore and Rs 10,000).
Novartis India executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc. and Pfizer Products Inc. on September 7, 2026, in connection with the transaction. The signing and closing of the transaction under the asset purchase agreement are to occur simultaneously.
Minipress, Minipres Trademark Acquisition
As detailed in Annexure I of the filing, the parties to the agreement are Novartis India Limited, Pfizer Inc. USA, and Pfizer Products Inc. USA.
The purpose of the agreement is the assignment of the ‘Minipress’ and ‘Minipres’ trademarks registered in India, together with certain related intellectual property rights, by Pfizer Inc. and Pfizer Products Inc. in favour of Novartis India.
The total aggregate consideration payable by Novartis India to the two Pfizer entities for the transaction is ₹1,250,00,10,000.
According to IQVIA MAT July 2026 data, Minipress XL recorded revenue of ₹228.6 crore and has been growing at a compound annual growth rate (CAGR) of 6.3% over the past four years, while the category has grown at a 9% CAGR during the same period.
Minipress XL contains prazosin and is primarily indicated in India for the treatment of hypertension (high blood pressure) and the management of urinary symptoms associated with benign prostatic hyperplasia (BPH).
No Related-Party Transaction
The filing further states that shareholding in the entity with whom the agreement is executed is not applicable.
The disclosure also records that there are no significant special rights under the agreement, such as the right to appoint directors, the first right to subscribe to shares in the event of an issuance, or the right to restrict changes in capital structure.
Novartis India clarified that the counterparties are not related to the promoter, promoter group, or group companies in any manner, and that the transaction does not fall within related-party transactions.
The filing also states that disclosures relating to the arm’s-length nature of the transaction, issuance of shares, loan agreements, and other related matters are not applicable.
In addition, the company has stated that the provisions concerning disclosure of details in the event of termination or amendment of the agreement are not applicable. These provisions include the names of the parties, nature of the agreement, date of execution, and details of any amendment or reasons for termination and their impact.
